Nephroplus Reports Q3 FY26 Results: Profit Rises to ₹84.52 Crore, Appoints Ravindra Tiwari to Senior Management
Nephrocare Health Services Limited reported its Q3 FY26 results. Standalone profit for the quarter was ₹84.52 crore, a turnaround from the previous quarter's loss. Consolidated profit for the quarter stood at ₹322.40 crore. The company also appointed Mr. Ravindra Tiwari as Senior Management Personnel, effective February 10, 2026.
The financial results show a strong positive trend in quarterly performance, and the appointment of a senior management member is important for governance. However, the nine-month results still show a loss, and the impact is tempered by the company's recent IPO which has already been factored into market expectations.
The company reported a significant improvement in profitability for the quarter, with a turnaround from a loss to a profit, indicating positive financial performance. The appointment of a new senior management personnel is also a constructive development.
Nephrocare Health Services Limited (NEPHROPLUS) announced its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors, in a meeting held on February 10, 2026, approved these results. The company reported a standalone profit after tax of ₹84.52 crore for the quarter ended December 31, 2025, a significant improvement compared to the loss of ₹324.14 crore in the previous quarter. For the nine months ended December 31, 2025, the standalone profit after tax stood at a loss of ₹189.48 crore. Consolidated profit after tax for the quarter ended December 31, 2025, was ₹322.40 crore, with a nine-month profit of ₹464.70 crore. The company also announced the designation of Mr. Ravindra Tiwari, Associate Vice President - Internal Audit, as Senior Management Personnel, effective February 10, 2026. Mr. Tiwari is a qualified Chartered Accountant with over 18 years of experience in Internal Audit, Risk Management, and Corporate Governance. The Board meeting commenced at 7:30 PM IST and concluded at 8:40 PM IST.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.